SGCB and persistent fetal circulation syndrome: These findings suggest that sGC stimulators/activators may be potentially used as alternative or adjuvant therapy for infants with iNO-resistant PPHN, while cinaciguat may provide a treatment option for PPHN aggravated by exposure to hyperoxia.